PEDIATRICS Vol. 77 No. 1 January 1986, pp. 99-103
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Manners, P. J.
Right arrow Articles by Ansell, B. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Manners, P. J.
Right arrow Articles by Ansell, B. M.

Slow-Acting Antirheumatic Drug Use in Systemic Onset Juvenile Chronic Arthritis

P. J. Manners MBBS, FRACP1 and B. M. Ansell MD1

1 Juvenile Rheumatism Unit, Taplow, and Clinical Research Centre, Northwick Park Hospital, Harrow, United Kingdom

The records of patients with systemic onset juvenile chronic arthritis were reviewed to study the effects of slow-acting antirheumatic drugs on systemic features of the disease and joint manifestations. Frequency and severity of side effects were also evaluated. The following conclusions resulted from this study. Most children could be treated with an alternate-day corticosteroid regimen. Gold and D-penicillamine treatment was not effective or tolerated during the systemic phase. However, after that phase, joint disease was controlled in 42% and 60% of children, respectively. Chlorambucil treatment was helpful in patients with amyloidosis and in those patients in whom all other drugs had failed. The incidence of side effects of chlorambucil are high, however. Antimalarial drug treatment was well tolerated but ineffective during the systemic phase. It was effective on joint disease alone in 44% of a small number of patients. Azathioprine treatment was well tolerated and effective in 50% of patients.

Key Words: slow-acting antirheumatic drug • D-penicillamine • gold • systemic juvenile chronic arthritis • antimalarial drug • azathioprine • chlorambucil

Submitted on August 6, 1984
Accepted on April 25, 1985




This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
J. L. Stephan, I. Kone-Paut, C. Galambrun, R. Mouy, B. Bader-Meunier, and A.-M. Prieur
Reactive haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients
Rheumatology, November 1, 2001; 40(11): 1285 - 1292.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
V. Gerloni, R. Cimaz, M. Gattinara, C. Arnoldi, I. Pontikaki, and F. Fantini
Efficacy and safety profile of cyclosporin A in the treatment of juvenile chronic (idiopathic) arthritis. Results of a 10-year prospective study
Rheumatology, August 1, 2001; 40(8): 907 - 913.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
R Munro, D R Porter, and R D Sturrock
Lymphadenopathy in a patient with systemic onset juvenile chronic arthritis
Ann Rheum Dis, September 1, 1998; 57(9): 513 - 517.
[Full Text]